Inhibition of the ubiquitin-proteasome system in Alzheimer's disease
Y. A. Lam,C. M. Pickart,A. Alban,M. Landon,C. Jamieson,R. Ramage,R. J. Mayer,Robert Layfield;Y. A. Lam;C. M. Pickart;A. Alban;M. Landon;C. Jamieson;R. Ramage;R. J. Mayer;Robert Layfield;
proceedings of the national academy of sciences2000Vol. 97pp. 9902-9906
191
layfield2000proceedingsinhibition
Abstract
Alzheimer's disease is the most common cause of dementia in the elderly. Although several genetic defects have been identified in patients with a family history of this disease, the majority of cases involve individuals with no known genetic predisposition. A mutant form of ubiquitin, termed Ub(+1), has been selectively observed in the brains of Alzheimer's patients, including those with nonfamilial Alzheimer's disease, but it has been unclear why Ub(+1) expression should be deleterious. Here we show that Ub(+1) is an efficient substrate for polyubiquitination in vitro and in transfected human cells. The resulting polyubiquitin chains are refractory to disassembly by deubiquitinating enzymes and potently inhibit the degradation of a polyubiquitinated substrate by purified 26S proteasomes. Thus, expression of Ub(+1) in aging brain could result in dominant inhibition of the Ub-proteasome system, leading to neuropathologic consequences.